Mix-and-Match COVID boosters tested in african teens and adults
NCT ID NCT07408297
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested different COVID-19 booster vaccines (Janssen, Moderna, Pfizer, Novavax) in about 1,900 adolescents and adults aged 12 to 64 in Kenya, Democratic Republic of Congo, and Rwanda. Some participants had HIV, and others did not. The goal was to see if mixing vaccine types for a booster shot is safe and boosts immunity. The trial is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
COVID-19 vaccines (Janssen Ad26COVS1, Moderna mRNA-1273, Pfizer-BioNTech, Novavax NVX-CoV2373)
What this could lead to
If successful, this could show that mixing different COVID-19 booster vaccines is safe and effective, especially for people with HIV, helping improve vaccine access in Africa.
What could go wrong
This is a phase 2 trial, so results are still early. The study focuses on immune response and safety, not direct prevention of COVID-19 illness. Different vaccine combinations may not all work equally well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Victoria Biomedical Research Institute
Kisumu, Kenya